Advertisement

Topics

Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis

2019-04-18 12:14:32 | BioPortfolio

Published on BioPortfolio: 2019-04-18T12:14:32-0400

Clinical Trials [262 Associated Clinical Trials listed on BioPortfolio]

Predictor of Clinical Response to Acthar in Myositis

Comparing the clinical effects of Acthar Gel before and after treatment and compare it to patients with inactive disease.

Environmental Risk Factors for Myositis in Military Personnel

Background: - Myositis is a rare disease in which the body s immune cells attack the muscle tissue. It can cause muscle weakness, swelling, and pain. It can develop in people wi...

Arimoclomol in Sporadic Inclusion Body Myositis

Inclusion body myositis (IBM) is the most common progressive and debilitating muscle disease beginning in persons over 50 years of age. This study will assess the safety and tolerability o...

Natalizumab in Inclusion Body Myositis (IBM)

Muscle biopsies of patients with Inclusion Body Myositis (IBM) have demonstrated a T-cell predominant inflammatory infiltrate, therefore, new agents targeting T -cell mediated cell death m...

Study of Pioglitazone in Sporadic Inclusion Body Myositis

A study looking at the effect of pioglitazone in skeletal muscle of patients with sporadic inclusion body myositis (sIBM).

PubMed Articles [101 Associated PubMed Articles listed on BioPortfolio]

Myositis autoantigen expression correlates with muscle regeneration but not autoantibody specificity.

Although more than a dozen myositis-specific autoantibodies (MSAs) have been identified, most myositis patients produce a single MSA. The specific overexpression of a given myositis autoantigen in myo...

CD8 +  cells as a predominant biomarker for inclusion body myositis.

Myositis is a heterogeneous group of muscular auto-immune diseases with clinical and pathological criteria that allow the classification of patients into different sub-groups. Inclusion body myositis ...

New insights in myositis-specific autoantibodies.

The aim of this study was to provide the most recent evidence on clinical utility of myositis-specific autoantibodies (MSAs) in the management of patients with myositis.

Celecoxib is a substrate of CYP2D6: Impact on celecoxib metabolism in individuals with CYP2C9*3 variants.

Celecoxib was characterized as a substrate of human cytochrome P450 (CYP) 2D6 in vitro. In recombinant CYP2D6, celecoxib hydroxylation showed atypical substrate inhibition kinetics with apparent K, K...

Focal Myositis of the Leg Presenting as Fever of Unknown Origin Detected by FDG PET/CT.

Focal myositis is an uncommon inflammatory pseudotumor of the skeletal muscle that may mimic neoplastic and inflammatory diseases. We present one case of focal myositis involving the left proximal vas...

Medical and Biotech [MESH] Definitions

A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN.

A disease characterized by bony deposits or the ossification of muscle tissue.

Inflammation of a muscle or muscle tissue.

Inflammation of the extraocular muscle of the eye. It is characterized by swelling which can lead to ischemia, fibrosis, or ORBITAL PSEUDOTUMOR.

A nonspecific tumor-like inflammatory lesion in the ORBIT of the eye. It is usually composed of mature LYMPHOCYTES; PLASMA CELLS; MACROPHAGES; LEUKOCYTES with varying degrees of FIBROSIS. Orbital pseudotumors are often associated with inflammation of the extraocular muscles (ORBITAL MYOSITIS) or inflammation of the lacrimal glands (DACRYOADENITIS).

More From BioPortfolio on "Novel PET Radioligands as Inflammatory Biomarkers in Rheumatoid Arthritis and Myositis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial